CoChat

What the gantenerumab trials teach us about Alzheimer's treatment

Schneider, Lon S. · 2023 · New England Journal of Medicine

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

An amyloid hypothesis1 for Alzheimer’s disease posits that amyloid-beta (Aβ) peptides cleaved from Aβ precursor protein trigger a neurodegenerative cascade, causing cognitive and functional impairment. The peptides have various lengths, ranging from monomers to self-assembled soluble oligomers, insoluble fibrils, and extracellular deposits, or plaques. Any of these species could be toxic. The antiamyloid monoclonal antibodies aducanumab2 and lecanemab3 have been approved by the Food and Drug Administration (FDA) for the treatment of early Alzheimer’s disease; donanemab4 seems to be headed for approval. Aducanumab and lecanemab received accelerated approval on the basis of a reduction in amyloid plaques. Lecanemab later received . . .

Overview

Integrity signals

Registry

Crossref · 10.1056/nejme2310903

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 12 references

Cited by

See all 6

Metadata

Authors
Schneider, L. S.
Affiliations
University of Southern California (US)
Corresponding author
Schneider, Lon S.
Venue
New England Journal of Medicine
Published
2023-11-16
Volume
389
Issue
20
Pages
1918-1920
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4388688083
Cited by
6
References
12
Citations by year
2025: 2 · 2024: 4
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
gantenerumab, Alzheimer's disease, amyloid-beta, amyloid hypothesis, anti-amyloid monoclonal antibodies, aducanumab, lecanemab, donanemab, amyloid plaques, accelerated FDA approval, clinical trial results
MeSH terms
Alzheimer Disease, Antibodies, Monoclonal, Humans, Amyloid beta-Peptides, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: What the gantenerumab trials teach us about Alzheimer's treatment. https://app.cochat.ai/papers/10.1056/nejme2310903
The paper
Schneider, L. S. (2023). What the gantenerumab trials teach us about Alzheimer's treatment. New England Journal of Medicine. https://doi.org/10.1056/nejme2310903

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.